176 related articles for article (PubMed ID: 38327651)
1. Aberrant Expressions of
Xiong YM; Zhou F; Zhou JW; Liu F; Zhou SQ; Li B; Liu ZJ; Qin Y
Curr Genomics; 2023 Dec; 24(6):368-384. PubMed ID: 38327651
[TBL] [Abstract][Full Text] [Related]
2. Deubiquitinase PSMD14 enhances hepatocellular carcinoma growth and metastasis by stabilizing GRB2.
Lv J; Zhang S; Wu H; Lu J; Lu Y; Wang F; Zhao W; Zhan P; Lu J; Fang Q; Xie C; Yin Z
Cancer Lett; 2020 Jan; 469():22-34. PubMed ID: 31634528
[TBL] [Abstract][Full Text] [Related]
3. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis.
Xiao H; Wang B; Xiong HX; Guan JF; Wang J; Tan T; Lin K; Zou SB; Hu ZG; Wang K
J Cell Physiol; 2021 Apr; 236(4):2572-2591. PubMed ID: 32853412
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
[TBL] [Abstract][Full Text] [Related]
5. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
6. Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection.
Lee JW; Hwang SH; Kim HJ; Kim D; Cho A; Yun M
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1984-1994. PubMed ID: 28695236
[TBL] [Abstract][Full Text] [Related]
7. High RPS11 level in hepatocellular carcinoma associates with poor prognosis after curative resection.
Zhou C; Sun J; Zheng Z; Weng J; Atyah M; Zhou Q; Chen W; Zhang Y; Huang J; Yin Y; Mao H; Zhang Z; Yi Y; Ren N
Ann Transl Med; 2020 Apr; 8(7):466. PubMed ID: 32395510
[TBL] [Abstract][Full Text] [Related]
8. Association of Increased Programmed Death Ligand 1 Expression and Regulatory T Cells Infiltration with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection.
Jeng LB; Li TC; Hsu SC; Teng CF
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746817
[TBL] [Abstract][Full Text] [Related]
9. High-mobility group protein box1 expression correlates with peritumoral macrophage infiltration and unfavorable prognosis in patients with hepatocellular carcinoma and cirrhosis.
Zhang QB; Jia QA; Wang H; Hu CX; Sun D; Jiang RD; Zhang ZL
BMC Cancer; 2016 Nov; 16(1):880. PubMed ID: 27836008
[TBL] [Abstract][Full Text] [Related]
10. The prognostic role of PSMD14 in head and neck squamous cell carcinoma.
Schnoell J; Scheiflinger A; Al-Gboore S; Kadletz-Wanke L; Kenner L; Heiduschka G; Jank BJ
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2483-2490. PubMed ID: 35750900
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of USP14 and PSMD14 expression in non-small cell lung cancer.
Lei J; Liu X; Liu W; Zhang Y; Liu Z
Ann Transl Med; 2021 Jun; 9(12):1019. PubMed ID: 34277819
[TBL] [Abstract][Full Text] [Related]
12. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
13. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein (a): a promising prognostic biomarker in patients with hepatocellular carcinoma after curative resection.
Gao XH; Zhang SS; Chen H; Wang K; Xie W; Wang FB
Onco Targets Ther; 2018; 11():5917-5924. PubMed ID: 30271176
[TBL] [Abstract][Full Text] [Related]
15. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.
Chen D; Xing W; Hong J; Wang M; Huang Y; Zhu C; Yuan Y; Zeng W
Ann Surg Oncol; 2012 Oct; 19(11):3556-65. PubMed ID: 22588469
[TBL] [Abstract][Full Text] [Related]
16. GNAO1 as a Novel Predictive Biomarker for Late Relapse in Hepatocellular Carcinoma.
Du M; Feng J; Tao Y; Pan Q; Chen F
J Healthc Eng; 2021; 2021():7631815. PubMed ID: 34900204
[TBL] [Abstract][Full Text] [Related]
17. Exonuclease 1 is a Potential Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma.
Ma J; Jin J; Lu H; Zhang J; Li Y; Cai X
Front Mol Biosci; 2022; 9():889414. PubMed ID: 35769911
[No Abstract] [Full Text] [Related]
18. Clinical Significance of TRMT6 in Hepatocellular Carcinoma: A Bioinformatics-Based Study.
Wang Y; Huang Q; Deng T; Li BH; Ren XQ
Med Sci Monit; 2019 May; 25():3894-3901. PubMed ID: 31128068
[TBL] [Abstract][Full Text] [Related]
19. A microRNA biomarker of hepatocellular carcinoma recurrence following liver transplantation accounting for within-patient heterogeneity.
Xie QY; Almudevar A; Whitney-Miller CL; Barry CT; McCall MN
BMC Med Genomics; 2016 Apr; 9():18. PubMed ID: 27059462
[TBL] [Abstract][Full Text] [Related]
20. A gene-based risk score model for predicting recurrence-free survival in patients with hepatocellular carcinoma.
Wang W; Wang L; Xie X; Yan Y; Li Y; Lu Q
BMC Cancer; 2021 Jan; 21(1):6. PubMed ID: 33402113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
